Overview

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Status:
Not yet recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

Study consists of a single arm to explore the efficacy and safery of zanubrutinib in patients with CD79B mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

BeiGene

Treatments:

Zanubrutinib